Navigation Links
New Study Shows Zylast Antiseptic Products Kill More than 99.99% of E. Coli, Other Bacteria, on Contact
Date:12/7/2012

TARRYTOWN, N.Y., Dec. 7, 2012 /PRNewswire/ -- Innovative BioDefense Inc, the creators of the Zylast® line of antimicrobial products, announced today that a new round of extensive time-kill testing on the Zylast products showed that more than 99.99 percent of disease-causing germs were destroyed within 15 seconds, making Zylast the most effective antimicrobial on the market.  The Zylast products, including an alcohol-based antiseptic, a water-based antiseptic lotion, and a foaming hand soap, were tested against a range of 25 different bacteria. 

The list of bacteria tested is standard, and was developed to ensure a broad, representative spectrum of organisms was evaluated.  Among the bacteria tested were E. Coli, a leading cause of food poisoning, S. Pneumoniae, a primary source of pneumonia and meningitis, and Acinetobacter baumannii, a drug-resistant bacteria that causes many fatal hospital infections and is prevalent in soldiers wounded in Iraq and Afghanistan.

Two of the most prevalent and dangerous of these drug-resistant bacteria are Methicillin-Resistant S. aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE).  Testing was performed with the Zylast Antiseptic against both of these deadly bacteria.  Not only did the Antiseptic destroy more than 99.99% of these bacteria on contact, it was still killing more than 90% of both VRE and MRSA one hour after it was applied.

All Zylast products have been shown to be persistent for six hours, and now have demonstrated rapid, broad-spectrum kill as well.  In-vitro testing on skin substitutes has shown that all Zylast products are still killing at or above 97% of disease-causing bacteria at 1 hour, and remaining above 90% at 4 hours after application.

When the Zylast Antiseptic was tested, it was shown to be more than 100 times more effective against Norovirus than alcohol alone (Liu et al, BioScience Results).  Previous t
'/>"/>

SOURCE Innovative BioDefense Inc
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Haemonetics Corporation (NYSE: HAE ) ... & EVP-Business Development, will present at The Deutsche Bank 38 ... Boston, MA on May 29, 2013 at 1:30pm ... The public may access Mr. Lindop,s presentation live ... Haemonetics Haemonetics (NYSE: HAE ) is ...
(Date:5/23/2013)... PAUL, Minn. , May 23, 2013  MGC ... Corporation), a global medical technology company, today scheduled a ... second quarter of fiscal year 2013, ended April 30, ... on Thursday, May 30, 2013. The Company will report ... 2013 after the markets close on Thursday, May 30, ...
(Date:5/23/2013)... -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a ... intellectual property developed and owned by Hadassah University ... research center, today announced that its portfolio company, ... the Israeli Ministry of Industry and Commerce, Office ... development and advance clinical trials. Cell Cure,s development ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
(Date:5/24/2013)... May 2013, Paris, France: Routinely measuring fractional flow ... angiography for diagnosis of chest pain leads to ... four patients, according to results from a study ... routine pressure wire assessment influence management strategy at ... was designed to assess whether routine assessment of ...
(Date:5/24/2013)... Oregon Health & Science University highlights an ingenious method ... the highly evasive HIV virus that causes AIDS. The ... approach to develop its own HIV vaccine candidate, which ... This latest research finding will be published in the ... . , "A major challenge in developing an ...
(Date:5/24/2013)... 2013 CBT News.com recently announced the addition ... web-based retail automotive industry news organization with 12 years experience ... to join a group that’s so forward-thinking in their approach,” ... online video content is on the rise.” , Atlanta born ... and segued into advertising at Cycle News and Boating World. ...
(Date:5/24/2013)... American International College of Arts ... articulation agreement with Old Dominion University (ODU) ... Antigua. , The program will permit ODU ... a cell biology course, taught by AICASA’s faculty, for ... University of Antigua (AUA) College of Medicine , students ...
(Date:5/24/2013)... children who missed more than half of recommended well-child ... compared to children who attended most of their visits, ... American Journal of Managed Care . The study included ... , Children with chronic conditions like asthma and ... when they missed visits, according to the study. ...
Breaking Medicine News(10 mins):Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2Health News:AICASA Signs Articulation Agreement with Old Dominion University to Create Study Abroad Program 2Health News:Young children who miss well-child visits are more likely to be hospitalized 2Health News:Young children who miss well-child visits are more likely to be hospitalized 3
... Wash., Sept. 15 Edifecs, the leader in ... has,selected the Edifecs Healthcare Accelerator Suite to automate ... and batch modes,within the product and development areas ... Sunny Singh, Edifecs, CEO said: "In response ...
... Misys Resolve Dispute, DALLAS, Sept. 15 iMedica ... dispute with Misys,Healthcare Systems LLC ("Misys")., Under the ... iMedica,PRM 2008 practice management (PM) and electronic health record ... its customers. The,agreement also states that iMedica will provide ...
... grant from the National Cancer Institute to find out ... tailored education in the user,s preferred language increases the ... The funding will be used to refine custom-designed software, ... evaluate its clinical impact in primary care physician,s offices ...
... Li, associate professor of biological sciences at Virginia ... cellular innate immunity network and human chronic inflammatory ... diseases. The finding presents a viable cellular and ... serious human inflammatory diseases, according to Li. ...
... advice , , MONDAY, Sept. 15 (HealthDay News) -- A ... about how they can preserve their ability to have ... , "It,s overwhelming for cancer patients to have ... same time that they are struggling to come to ...
... 15 Optical Cable,Corporation (Nasdaq: OCCF ), announced ... 2008 results today, September 15, 2008. The third,quarter results ... 2008. In conjunction with its release, the Company will ... 10:00 a.m. Eastern Time., Individuals wishing to participate ...
Cached Medicine News:Health News:Unisys Selects Edifecs Healthcare Accelerator Suite(TM) for MMIS System 2Health News:iMedica Announces Agreement with Misys 2Health News:UC Davis doctors use multimedia to increase colorectal cancer screening among Hispanics 2Health News:Key protein molecule linked to diverse human chronic inflammatory diseases 2Health News:Web Site Helps Cancer Patients With Fertility Preservation 2Health News:Optical Cable Corporation Schedules Conference Call to Discuss Third Quarter 2008 Results 2Health News:Optical Cable Corporation Schedules Conference Call to Discuss Third Quarter 2008 Results 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: